Monograph Details
|
|
Cardiovascular System
> Hypertension
|
|
CARDENE IV |
| Manufacturer |
|
PDL BioPharma, Inc. |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Calcium channel blocker (dihydropyridine). |
| Generic Name |
|
Nicardipine HCl 2.5mg/mL; for slow IV infusion (after dilution to 0.1mg/mL solution). |
| Also |
• CARDENE SR
• Nicardipine
|
| Indications |
|
Hypertension. |
| Children |
|
<18yrs: not recommended. |
| Adults |
|
Individualize; see literature. |
| Contraindications |
|
Advanced aortic stenosis. |
| Precautions |
|
Cardiac failure. Angina. Acute cerebral infarction or hemorrhage. Hepatic or renal impairment. Pheochromocytoma. For regular capsules: measure blood pressure (BP) 1–2 hrs and 8 hrs after dosing. For SR: measure BP at 2–4 hrs and at end of dosing interval. For IV: monitor BP before and during infusion; avoid rapid or excessive reductions; switch to oral form when possible. Pregnancy (Cat.C). Nursing mothers: not recommended. |
| Interactions |
|
Potentiated by cimetidine. Increases serum levels of cyclosporine, possibly digoxin. |
| Adverse Reactions |
|
Increased angina, flushing (caps, SR), headache, pedal edema, asthenia, dizziness, somnolence (caps), tachycardia, GI upset, sweating; ECG abnormalities, orthostatic hypotension, ventricular extrasystoles, local reactions (inj). |
| How Supplied |
Caps 20mg, 30mg—contact supplier
SR—60
IV (10mL amps)—10 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
